Business
Lantern Pharma Inc.: We have a limited operating history and have never generated any revenues other than from research grants, which may make it difficult to evaluate the success of our business to date and to assess our future viability.
Net income increased 17.6% to ($17.1M), while Operating cash flow increased 12.0% to ($15.7M).
The read at a glance✓ Audited against SEC data
- Scale — FY2025 revenue N/AWatch
- Profitability — Net income ($17.1M)Watch
- Cash generation — Free cash flow ($15.7M)Note
- Accounting — No applicable forensic screenNote
- Insiders — 0 buys; 0 sells in 365 daysNote
- Capital — Comparable payout data unavailableNote
Leadership changes
From Lantern Pharma Inc.'s own filings, the day they're filed.
- Lee T. Schalop · Chief Business Officer · appointment
Latest filings
- 8-K · Company announcement2026-08-14
- 10-Q · Quarterly report2026-08-14
- 8-K · Company announcement2026-08-03
- 8-K · Company announcement2026-06-02
- 8-K · Company announcement2026-05-15
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Lantern Pharma Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.